Logo

UnitedHealthcare Issues Positive Coverage Decision for VeriStrat

May 12, 2015 | staff reporter

NEW YORK (GenomeWeb) – Biodesix today announced that UnitedHealthcare has issued a positive coverage decision for the VeriStrat test for advanced non-small cell lung cancer. 

UnitedHealthcare covers 44.7 million lives in the US. 

VeriStrat is a blood-based proteomic test that provides prognostic and predictive data to help guide treatment of patients with advanced NSCLC. Those with VeriStrat Poor test results have a shorter medical overall survival that those with VeriStrat Good results, Boulder, Colorado-based Biodesix said. 

Last month CareFirst Blue Cross Blue Shield issued a positive coverage decision for the test. 

Filed under

Molecular Diagnostics
Business News
Proteomics & Protein Research
payor coverage
non-small cell lung cancer
Biodesix
UnitedHealthCare
Breaking News
The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.